Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Apr 17, 3:05PM CDT

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones GlobeNewswire - Wed Mar 18, 3:05PM CDT

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected...

FDMT : 9.42 (-0.32%)
4DMT to Participate in Upcoming Investor Meetings GlobeNewswire - Mon Mar 16, 7:00AM CDT

EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)
4DMT to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Feb 19, 7:00AM CST

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Feb 13, 3:05PM CST

EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD GlobeNewswire - Mon Feb 9, 7:00AM CST

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections  4FRONT-1 overenrolled and expected...

FDMT : 9.42 (-0.32%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Sat Jan 17, 7:00AM CST

EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)
4DMT Provides Company Update and Anticipated Development Milestones for 2026 GlobeNewswire - Wed Jan 7, 7:00AM CST

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as...

FDMT : 9.42 (-0.32%)
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease GlobeNewswire - Wed Dec 17, 2025

Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2  Durable CFTR transgene expression within target...

FDMT : 9.42 (-0.32%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Dec 12, 2025

EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.42 (-0.32%)

Barchart Exclusives

Warren Buffett’s Berkshire Hathaway Is Losing Money in This Dividend Stock: Can It Work for You? Barchart - Tue Apr 28, 6:30PM CDT
Domino's Pizza has a dividend yield of 2.4%, and its dividends have risen at an annualized pace of nearly 20% over the last 10 years. Does that make the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.